Zymeworks Inc.
NASDAQ:ZYMEBiotechnology
-$0.38 today
- Market cap
- $1.80B
- Beta
- 1.14
- P/E (TTM)
- -16.6
- EPS (TTM)
- -$1.37
Volume 0.57M
Average 0.71M
ZYME Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Zymeworks Inc.NASDAQ: ZYME
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization declines year over year
Q3 FY2026 depreciation & amortization of $1.72M fell 33.6% year over year, ahead of the -35.8% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 12.1% from the prior quarter. Over 3 fiscal years it compounded at -2.5% a year.
Context
- Depreciation & amortization amounted to 10.5% of revenue in FY2025, down 4.2 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of -33.6% holds above the trailing-twelve-month pace of -35.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 11.11M USD
- Year-over-year change
- -0.7%
- 4-year CAGR
- +3.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 11.11M | -0.7% |
| FY2024 | 2024-12-31 | 11.19M | -35.3% |
| FY2023 | 2023-12-31 | 17.31M | +44.2% |
| FY2022 | 2022-12-31 | 12M | +25.3% |
| FY2021 | 2021-12-31 | 9.58M | — |
Depreciation & Amortization vs competitors
How ZYME compares with its peers on the latest reported figures
- ZYME's LTM Sep 2026 depreciation & amortization of $8.21M is the 3rd highest of the 11 companies compared; the peer median is $1.97M.
- Its year-over-year change of -35.8% is the 8th highest of 10, against a peer median of -22.3%.
- Depreciation & amortization amounts to 3.1% of revenue for ZYME, versus a peer median of 2.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $14.4M | -22.3% | +20.4% | 2.1% | |
| LTM Jun 2026 | $10.17M | -10.7% | +6.1% | 9.7% | |
| LTM Sep 2026 | $8.21M | -35.8% | -2.5% | 3.1% | |
| LTM Mar 2026 | $7.09M | -5.1% | -15.4% | 4.5% | |
| LTM Sep 2026 | $3.73M | +10.4% | +5.3% | 3333.9% | |
| LTM Sep 2026 | $2.69M | -3.0% | +67.3% | — | |
| LTM Mar 2026 | $1.24M | -26.3% | -17.4% | 3.5% | |
| LTM Mar 2026 | $1.19M | -63.3% | -7.7% | 1.5% | |
| LTM Mar 2026 | $645K | -25.8% | +27.3% | — | |
| LTM Mar 2026 | $148K | -99.6% | -26.0% | 1.2% | |
| LTM Mar 2026 | $0 | — | -0.5% | 0.0% | |
| Peer median (excluding ZYME) | $1.97M | -22.3% | +2.4% | 2.8% | |
Competitors are the stored peer set for ZYME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 26.68M | 412.48M | 76.01M | 76.3M | 105.97M |
| Cost of Revenue | 0 | 0 | 142.99M | 0 | 0 |
| Gross Profit | 26.68M | 412.48M | (66.98M) | 76.3M | 105.97M |
| Gross Margin | 100.0% | 100.0% | -88.1% | 100.0% | 100.0% |
| Research & Development | 199.75M | 208.6M | 143.62M | 134.62M | 137M |
| Selling, General & Admin | 42.6M | 73.4M | 70.4M | 61.5M | 61.5M |
| Operating Expenses | 242.31M | 281.95M | 71.08M | 213.41M | 198.5M |
| Depreciation & Amortization | 9.58M | 12M | 17.31M | 11.19M | 11.11M |
| EBITDA | (206.09M) | 142.49M | (120.7M) | (108.62M) | (68.64M) |
| EBITDA Margin | -772.4% | 34.5% | -158.8% | -142.4% | -64.8% |
| Operating Income | (215.63M) | 130.53M | (138.05M) | (137.11M) | (92.54M) |
| Operating Margin | -808.2% | 31.6% | -181.6% | -179.7% | -87.3% |
| Interest Income | 1.97M | 3.6M | 19.71M | 19.94M | 13.35M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 3.27M | 4.71M | 18.81M | 20.5M | 12.78M |
| Income Before Tax | (212.36M) | 135.23M | (119.24M) | (116.61M) | (79.75M) |
| Pre-Tax Margin | -795.9% | 32.8% | -156.9% | -152.8% | -75.3% |
| Income Tax Expense | (516K) | 10.89M | (568K) | 6.08M | 1.38M |
| Net Income | (211.84M) | 124.34M | (118.67M) | (122.7M) | (81.13M) |
| Net Margin | -794.0% | 30.1% | -156.1% | -160.8% | -76.6% |
| EPS (Basic) | (4.06) | 1.91 | (1.72) | (1.62) | (1.08) |
| EPS (Diluted) | (4.61) | 1.90 | (1.72) | (1.62) | (1.08) |
| Weighted Avg Shares | 52.13M | 65.19M | 68.86M | 75.85M | 75.34M |
| Weighted Avg Shares (Diluted) | 52.13M | 65.25M | 68.86M | 75.88M | 75.34M |
Zymeworks Inc.
NASDAQ:ZYME
Intrinsic Alpha fair value
Locked
Current Price
$25.84
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.